Health AI Central
Peer-Reviewed Publication
Leukemia2026October 6, 2026Journal Article

MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.

Thierry Facon1, Gordon Cook2, Saad Z Usmani3, Cyrille Hulin4, Shaji Kumar5, Cyrille Touzeau6, Nizar J Bahlis7, Supratik Basu8, Hartmut Goldschmidt9, Hang Quach10, Mohamad Mohty11, Christopher P Venner12,13, Katja Weisel14, Noopur Raje15, Salomon Manier16, Mai Ngo17, Marjohn Armoon18, Kasey Bolyard19, Fredrik Borgsten19, Robin Carson20, Sonja Zweegman21
1University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France.
2Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
3Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
5Department of Hematology, Mayo Clinic Rochester, Rochester, MN, USA.
6Centre Hospitalier Universitaire, Nantes, France.
7Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
8Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, UK.
9GMMG-Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany.
10University of Melbourne, St Vincent's Hospital, Melbourne, VIC, Australia.
11Hematology and Cellular Therapy Department of Saint-Antoine Hospital, Sorbonne University, Paris, France.
12Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
13BC Cancer-Vancouver Centre, Vancouver, BC, Canada.
14Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
15Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
16University of Lille, CHU de Lille, Hôpital Huriez, Service d'Hématologie, Lille, France.
17Cytel, Cambridge, MA, USA.
18Johnson & Johnson, Horsham, PA, USA.
19Johnson & Johnson, Raritan, NJ, USA.
20Johnson & Johnson, Spring House, PA, USA.
21Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands. s.zweegman@amsterdamumc.nl.
PubMed DOI

Abstract

In MAIA (Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) and overall survival (OS) versus Rd in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Here, we report an updated subgroup analysis by frailty status. We ret…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.